Author Archive

Patient Advocates Hail Synchronization as Commonsense Tool

by Amanda Conschafter, Blog Editor Patients with chronic conditions may undermine their own wellness by straying from their physicians’ instructions.  Medical non-adherence – that is, skipping

Read More

Coverage for Obesity Treatments Could Lower Long-term Costs

by Amanda Conschafter, Blog Editor Medicaid coverage for obesity treatments could save money over the long term, suggests a new policy brief from the Institute for Patient Access. 

Read More

Headache Patients Face Limited Options, Despite Prevalence and Pain

by Amanda Conschafter, Blog Editor Far more than an occasional nuisance, headaches interfere with countless Americans’ daily lives – and cost the country $31 billion annually.  Yet the

Read More

Biologic Therapy Substitution to be Considered by World Health Assembly

by Renee Klink, Social Media Director Recently two World Health Organization resolutions were approved for consideration at the 67th World Health Assembly, to convene this coming May

Read More

340B Controversy Jeopardizes Patient Access

by Amanda Conschafter, Blog Editor When big hospitals profit by gaming a government program, public confidence wanes – and patient access could suffer. That’s the concern with

Read More

High Co-Pays Inhibit Access for Cancer Patients

You can’t put a price on health, the saying goes. But for certain leukemia patients who need protein kinase inhibitor treatment, cost can prove to be not only a key factor but also a barrier to wellness.

Will Proposed CMS Rule Threaten Access for Seniors?

Medicare has money problems; that’s no secret. But health experts worry that a newly proposed rule to reduce costs by ending Part D’s access guarantee for specific medications could shake Medicare’s fundamental purpose: to keep America’s seniors healthy.

New IfPA Paper: Why Doctors Need to Know When Pharmacists Substitute Biological Medicines

Today the Institute for Patient Access released a new policy brief entitled “WHY DOCTORS NEED TO KNOW WHEN PHARMACISTS SUBSTITUTE BIOLOGICAL MEDICINES.” In this edition of IfPA’s “The Physician’s Perspective,” David Charles, M.D. and Mary Ann Chapman, PhD succinctly set forward the benefits of physician notice and rebut the arguments against physician notice. You can read the policy brief here.

Back to Top